LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T
All content for Oncology Data Advisor is the property of i3 Health and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T
Charting New Paths in Oncology Informatics With Travis Osterman, DO, and Waqas Haque, MD, MPH
Oncology Data Advisor
17 minutes 35 seconds
1 month ago
Charting New Paths in Oncology Informatics With Travis Osterman, DO, and Waqas Haque, MD, MPH
Read the full article at: https://oncdata.com/travis-osterman-ai-informatics
In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Dr. Travis Osterman, Director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center, about the evolving role of health informatics in oncology. Their conversation spans training pathways, precision oncology, data standards, AI integrations, and the strategies to promote adoption in both academic and community practices.
Oncology Data Advisor
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T
